Dr. Choi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
119 Belmont St
Worcester, MA 01605Phone+1 508-334-2846Fax+1 508-856-3981
Education & Training
- Dana-Farber Cancer InstitutePost-Doctoral Fellowship, 2003 - 2008
- Massachusetts General HospitalFellowship, Gastroenterology, 2000 - 2005
- University of California (San Francisco)Residency, Internal Medicine, 1997 - 2000
- Weill Cornell MedicineClass of 1997
Certifications & Licensure
- CA State Medical License 1999 - Present
- MA State Medical License 2003 - 2026
- NH State Medical License 2024 - 2026
- ME State Medical License 2010 - 2025
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- 1 citationsConserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in HSCs.Cheng Sun, Chan Zhou, Kaveh Daneshvar, Amel Ben Saad, Arcadia J Kratkiewicz
Hepatology. 2024-04-02 - 28 citationsA role for intestinal alkaline phosphatase in preventing liver fibrosis.Yang Liu, Paul M Cavallaro, Byeong-Moo Kim, Tao Liu, Hongyan Wang
Theranostics. 2021-01-01 - Author Correction: Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosisByeong-Moo Kim, Ahmed Maher Abdelfattah, Robin Vasan, Bryan C. Fuchs, Michael Y. Choi
Scientific Reports. 2020-06-19
Lectures
- Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Enzyme Treatment Reduces Alcohol-Induced Liver Damage in Mouse ModelsApril 25th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: